{"filing":{"accession_number":"0001640334-26-001447","cik":"0001622996","ticker":"ACBM","company_name":"ACRO BIOMEDICAL CO., LTD.","form":"8-K","filing_date":"2026-09-02","report_date":"2026-09-02","primary_document":"acbm_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1622996/000164033426001447/acbm_8k.htm"},"events":[{"id":31286,"run_id":28701,"accession_number":"0001640334-26-001447","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.65,"summary":"Yu-Ting Su resigned as director, chairman and chief executive officer on September 2, 2026, effective upon successor appointment. While the filing also discloses two concurrent appointments (Shao-Hsiang Shih as chairman and Jing-Zhou Chen as CEO/CFO), the primary disclosed action centers on the departure of the sitting CEO and chairman, making exec_departure the most salient event. The confidence is moderate because the filing presents a simultaneous leadership transition with multiple appointments, which could also support an exec_appointment classification; however, the opening paragraph emphasizes Su's resignation as the triggering event.","company_name":"ACRO BIOMEDICAL CO., LTD.","ticker":"ACBM","filing_date":"2026-09-02","form":"8-K","submitted_at":null,"items":[{"id":34118,"accession_number":"0001640334-26-001447","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.65,"reasoning":"Yu-Ting Su resigned as director, chairman and chief executive officer on September 2, 2026, effective upon successor appointment. While the filing also discloses two concurrent appointments (Shao-Hsiang Shih as chairman and Jing-Zhou Chen as CEO/CFO), the primary disclosed action centers on the departure of the sitting CEO and chairman, making exec_departure the most salient event. The confidence is moderate because the filing presents a simultaneous leadership transition with multiple appointments, which could also support an exec_appointment classification; however, the opening paragraph emphasizes Su's resignation as the triggering event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T20:06:57.166570+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34118,"accession_number":"0001640334-26-001447","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.65,"reasoning":"Yu-Ting Su resigned as director, chairman and chief executive officer on September 2, 2026, effective upon successor appointment. While the filing also discloses two concurrent appointments (Shao-Hsiang Shih as chairman and Jing-Zhou Chen as CEO/CFO), the primary disclosed action centers on the departure of the sitting CEO and chairman, making exec_departure the most salient event. The confidence is moderate because the filing presents a simultaneous leadership transition with multiple appointments, which could also support an exec_appointment classification; however, the opening paragraph emphasizes Su's resignation as the triggering event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T20:06:57.166570+00:00","company_name":"ACRO BIOMEDICAL CO., LTD.","ticker":"ACBM","filing_date":"2026-09-02"}]}